地塞米松前房内药物递送混悬液治疗白内障术后炎症:一项随机安慰剂对照III期试验
这项前瞻性随机双盲多中心试验纳入394例接受单侧超声乳化白内障手术的患者,按1:2:2随机接受前房内注射安慰剂或342 μg、517 μg IBI-10090地塞米松药物递送混悬液。术后第8天,342 μg和517 μg组前房细胞清除率分别为63.1%和66.0%,均高于安慰剂组的25.0%(P < 0.001);三组不良事件相似,至术后第90天未报告严重眼部不良事件。
要点
- 术后第8天前房细胞清除率:342 μg组63.1%、517 μg组66.0%,均高于安慰剂组25.0%(P < 0.001)。
- 术后第8天前房闪辉清除率:342 μg组92.4%、517 μg组89.1%,均高于安慰剂组63.8%(P < 0.001)。
- 三组不良事件相似,至术后第90天未报告严重眼部不良事件。
核心结论
- 白内障术后前房内放置342和517 μg IBI-10090地塞米松药物递送混悬液治疗术后炎症安全有效,可能成为该患者人群皮质类固醇滴眼液的替代选择。
研究设计与样本
- 前瞻性、随机、双盲、多中心试验,394例患者按1:2:2随机接受前房内注射5 μl安慰剂或5 μl含342 μg或517 μg IBI-10090地塞米松药物递送混悬液,术后随访90天。
主要发现
- 术后第8天前房细胞清除(前房细胞评分0)率:安慰剂组25.0%,342 μg组63.1%,517 μg组66.0%(P < 0.001)。
- 术后第8天前房闪辉清除率:安慰剂组63.8%,342 μg组92.4%,517 μg组89.1%(P < 0.001)。
- 术后第8天前房细胞加闪辉清除率:安慰剂组33.8%,342 μg组63.1%,517 μg组67.3%(P < 0.001)。
- 三组不良事件相似,至术后第90天未报告严重眼部不良事件。
关键数值与推荐
- 术后第8天前房细胞清除率:342 μg组63.1%、517 μg组66.0%,均高于安慰剂组25.0%(P < 0.001)。
- 术后第8天前房闪辉清除率:342 μg组92.4%、517 μg组89.1%,均高于安慰剂组63.8%(P < 0.001)。
- 术后第8天前房细胞加闪辉清除率:342 μg组63.1%、517 μg组67.3%,均高于安慰剂组33.8%(P < 0.001)。
临床怎么用
- 作者认为,白内障术后前房内放置342和517 μg IBI-10090地塞米松药物递送混悬液治疗术后炎症安全有效,可能成为该患者人群皮质类固醇滴眼液的替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and efficacy of an anterior chamber intracameral dexamethasone drug-delivery suspension (IBI-10090; DEXYCU; Icon Bioscience Inc., Newark, CA) that provides medication for up to 21 days with a single application in treating postoperative inflammation in patients undergoing cataract surgery. DESIGN: Prospective, randomized, double-masked, multicenter trial. PARTICIPANTS: Patients with preoperative best-corrected visual acuity of 20/30 to 20/200 undergoing unilateral cataract surgery by phacoemulsification were randomized to receive IBI-10090 or placebo. METHODS: Three hundred ninety-four patients were randomized 1:2:2 to receive 5-μl injections of placebo or 5-μl injections of 342 or 517 μg IBI-10090 dexamethasone drug delivery suspension injected into the anterior chamber at the conclusion of cataract surgery. Patients were followed for 90 days after surgery. MAIN OUTCOME MEASURES: Primary outcome was anterior chamber cell (ACC) clearing (ACC score of 0) in the study eye at postoperative day (POD) 8. Secondary outcome measures were anterior chamber flare and ACC plus flare clearing in the study eye. Ocular and nonocular adverse events were assessed. RESULTS: Anterior chamber cell clearing at POD 8 was achieved in 25.0% of eyes in the placebo group and in 63.1% and 66.0% of eyes in the 342- and 517-μg treatment groups, respectively (P < 0.001). Anterior chamber flare clearing at POD 8 was achieved by 63.8% of eyes in the placebo group and in 92.4% and 89.1% of eyes in the 342- and 517-μg IBI-10090 treatment groups, respectively (P < 0.001). Anterior chamber cell plus flare clearing at POD 8 was achieved in 33.8% of eyes receiving placebo and in 63.1% and 67.3% of eyes receiving 342- and 517-μg IBI-10090, respectively (P < 0.001). Adverse events among the 3 groups were similar, and no serious ocular adverse events were reported up to POD 90. CONCLUSIONS: The IBI-10090 dexamethasone drug-delivery suspension placed in the anterior chamber after cataract surgery at concentrations of 342 and 517 μg was safe and effective in treating inflammation occurring after cataract surgery and may be an alternative to corticosteroid drop installation in this patient population.
引用
- Donnenfeld E, Holland E. Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Cataract Surgery: A Randomized, Placebo-Controlled, Phase III Trial. Ophthalmology. 2018. PMID: 29397189. doi:10.1016/j.ophtha.2017.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。